Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 160

Similar articles for PubMed (Select 22857752)

1.

Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?

Karaolides T, Skolarikos A, Bourdoumis A, Konandreas A, Mygdalis V, Thanos A, Deliveliotis C.

Urology. 2012 Aug;80(2):354-9. doi: 10.1016/j.urology.2012.03.067.

PMID:
22857752
2.

Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?

Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P.

BJU Int. 2012 Feb;109(4):549-56. doi: 10.1111/j.1464-410X.2011.10374.x. Epub 2011 Jun 28.

PMID:
21711438
3.

HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study.

Geavlete B, Jecu M, Multescu R, Georgescu D, Geavlete P.

Urology. 2010 Sep;76(3):664-9. doi: 10.1016/j.urology.2010.02.067. Epub 2010 Jun 8.

PMID:
20627289
4.
5.

Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.

Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S.

BJU Int. 2011 Oct;108(8 Pt 2):E297-303. doi: 10.1111/j.1464-410X.2011.10090.x. Epub 2011 Mar 17.

PMID:
21414125
7.

A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.

Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, Nseyo U, Droller MJ; PC B302/01 Study Group.

J Urol. 2007 Jul;178(1):62-7. Epub 2007 May 11.

PMID:
17499283
8.

Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.

Daniltchenko DI, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, Loening SA, Schnorr D.

J Urol. 2005 Dec;174(6):2129-33, discussion 2133.

PMID:
16280742
9.

Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer.

Ray ER, Chatterton K, Thomas K, Khan MS, Chandra A, O'Brien TS.

J Endourol. 2009 Jun;23(6):983-8. doi: 10.1089/end.2008.0642.

PMID:
19441882
10.
11.
12.

Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy.

Kriegmair M, Zaak D, Rothenberger KH, Rassweiler J, Jocham D, Eisenberger F, Tauber R, Stenzl A, Hofstetter A.

J Urol. 2002 Aug;168(2):475-8.

PMID:
12131291
13.

[Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study].

Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Rössler W.

Urologe A. 2003 Oct;42(10):1366-73. Epub 2003 Apr 25. German.

PMID:
14569386
14.

Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.

Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M.

J Urol. 2012 Jul;188(1):58-62. doi: 10.1016/j.juro.2012.03.007. Epub 2012 May 12.

15.

Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.

Burger M, Stief CG, Zaak D, Stenzl A, Wieland WF, Jocham D, Otto W, Denzinger S.

Urology. 2009 Dec;74(6):1282-6. doi: 10.1016/j.urology.2009.06.088. Epub 2009 Oct 12.

PMID:
19819538
16.

Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors.

Geavlete B, Multescu R, Georgescu D, Geavlete P.

J Endourol. 2009 Jun;23(6):977-81. doi: 10.1089/end.2008.0574.

PMID:
19473068
17.
18.

Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial.

Gkritsios P, Hatzimouratidis K, Kazantzidis S, Dimitriadis G, Ioannidis E, Katsikas V.

Int Urol Nephrol. 2014 May;46(5):927-33. doi: 10.1007/s11255-013-0603-z. Epub 2013 Nov 19.

PMID:
24249423
19.

[Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer].

Danil'chenko DI, Koenig F, Riedl K, Schnorr D, Waldman A, Al-Shukri S, Loening SA.

Vopr Onkol. 2003;49(6):734-7. Russian.

PMID:
14976918
20.

Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.

Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, Kriegmair M, Karl A, Shen Y, Grossman HB.

J Urol. 2010 Nov;184(5):1907-13. doi: 10.1016/j.juro.2010.06.148. Epub 2010 Sep 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk